Cargando…

Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study

OBJECTIVES: To assess long-term golimumab efficacy/safety in patients with active psoriatic arthritis (PsA). METHODS: Adult PsA patients (≥3 swollen, ≥3 tender joints, active psoriasis) were randomly assigned to subcutaneous injections of placebo, golimumab 50 mg or 100 mg every 4 weeks (q4wks) thro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kavanaugh, Arthur, McInnes, Iain B, Mease, Philip J, Krueger, Gerald G, Gladman, Dafna D, van der Heijde, Désirée, Mudivarthy, Surekha, Xu, Weichun, Mack, Michael, Xu, Zhenhua, Beutler, Anna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2013
Materias:	Clinical and Epidemiological Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3812864/ https://www.ncbi.nlm.nih.gov/pubmed/23161902 http://dx.doi.org/10.1136/annrheumdis-2012-202035

Ejemplares similares

Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placebo‐Controlled Study
por: Kavanaugh, Arthur, et al.
Publicado: (2016)

Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)
por: Kavanaugh, Arthur, et al.
Publicado: (2014)

Patient-Reported Outcomes and the Association With Clinical Response in Patients With Active Psoriatic Arthritis Treated With Golimumab: Findings Through 2 Years of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
por: Kavanaugh, Arthur, et al.
Publicado: (2013)

Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab
por: Wagner, Carrie L, et al.
Publicado: (2013)

Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research
por: van der Heijde, Désirée, et al.
Publicado: (2020)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
por: Braun, Jürgen, et al.
Publicado: (2014)

Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial
por: Mease, Philip J, et al.
Publicado: (2017)

Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations
por: Mease, Philip J., et al.
Publicado: (2020)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
por: Braun, Jürgen, et al.
Publicado: (2011)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
por: Braun, Jürgen, et al.
Publicado: (2011)

Erratum to: Secukinumab: A New Treatment Option for Psoriatic Arthritis
por: Mease, Philip, et al.
Publicado: (2016)

Evaluation of Improvement in Skin and Nail Psoriasis in Bio‐naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO‐VIBRANT Study
por: Mease, Philip, et al.
Publicado: (2020)

Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT
por: Gladman, Dafna D, et al.
Publicado: (2010)

Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study
por: Kavanaugh, A, et al.
Publicado: (2015)

Safety and Efficacy of Intravenous Golimumab in Patients With Active Psoriatic Arthritis: Results Through Week Twenty‐Four of the GO‐VIBRANT Study
por: Kavanaugh, Arthur, et al.
Publicado: (2017)

Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial
por: Mease, Philip, et al.
Publicado: (2020)

The association between sonographic enthesitis and radiographic damage in psoriatic arthritis
por: Polachek, Ari, et al.
Publicado: (2017)

Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
por: Mease, Philip J, et al.
Publicado: (2017)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
por: Deodhar, Atul, et al.
Publicado: (2015)

Correction to: The association between sonographic enthesitis and radiographic damage in psoriatic arthritis
por: Polachek, Ari, et al.
Publicado: (2019)

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis
por: van der Heijde, Désirée, et al.
Publicado: (2016)

Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials
por: Mease, Philip J., et al.
Publicado: (2021)

Efficacy and Safety of Intravenous Golimumab Through One Year in Patients With Active Psoriatic Arthritis
por: Husni, M. Elaine, et al.
Publicado: (2020)

Psoriatic arthritis
por: Ocampo D, Vanessa, et al.
Publicado: (2019)

The effect of intravenous golimumab on health-related quality of life and work productivity in patients with active psoriatic arthritis: results of the Phase 3 GO-VIBRANT trial
por: Ogdie, Alexis, et al.
Publicado: (2021)

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials
por: Mease, Philip J, et al.
Publicado: (2021)

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis
por: Ogdie, Alexis, et al.
Publicado: (2023)

Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1–3 pooled analysis
por: Kavanaugh, Arthur, et al.
Publicado: (2019)

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
por: Wagner, Carrie, et al.
Publicado: (2011)

Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study
por: Inman, Robert D., et al.
Publicado: (2016)

Recent advances in understanding and managing psoriatic arthritis
por: Gladman, Dafna D.
Publicado: (2016)

Synovial Tissue Response to Treatment in Psoriatic Arthritis
por: Codullo, Veronica, et al.
Publicado: (2011)

Classification and Outcome Measures for Psoriatic Arthritis
por: Leung, Ying Ying, et al.
Publicado: (2018)

Efficacy and safety of golimumab in patients with non-radiographic axial spondyloarthritis: a withdrawal and retreatment study (GO-BACK)
por: Weinstein, Cindy L J, et al.
Publicado: (2023)

4-year results from the RAPID-PsA phase 3 randomised placebo-controlled trial of certolizumab pegol in psoriatic arthritis
por: van der Heijde, Désirée, et al.
Publicado: (2018)

Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials
por: Mease, Philip, et al.
Publicado: (2022)

Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis
por: McInnes, Iain B., et al.
Publicado: (2021)

Treatment guidelines in psoriatic arthritis
por: Ogdie, Alexis, et al.
Publicado: (2020)

Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase III Trial
por: Kavanaugh, Arthur, et al.
Publicado: (2015)

Role of golimumab, a TNF-alpha inhibitor, in the treatment of the psoriatic arthritis
por: Michelon, Melissa A, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_7oho4g5qbohp3rusbutn67fbfa